Tyra Biosciences: Buy Rating Reiterated as SURF302 Data Upside Beckons; 12‑Month Price Target Maintained at $45
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright reiterated a Buy rating on Tyra Biosciences (TYRA) with a $45 price target, citing confidence in upcoming SURF302 data for NMIBC and limited current valuation credit. Canaccord Genuity also maintained a Buy rating with a $50 target. Analysts highlight potential upside from strong efficacy expectations despite downside risks if initial readouts disappoint.
H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on TYRA stock, giving a Buy rating on August 25.
Mitchell Kapoor has given his Buy rating due to a combination of factors, notably his view that upcoming SURF302 data in NMIBC is being presented with unusual transparency and confidence by management. He anticipates a strong three‑month complete response profile, with pooled CR rates at or above 70% across the 50mg and 60mg cohorts and a favorable safety profile marked by only low single‑digit rates of serious adverse events.
Kapoor also emphasizes that the current valuation gives limited credit to Tyra’s NMIBC program, creating meaningful upside if efficacy and tolerability meet expectations and later durability data are supportive. While he acknowledges downside risk if the initial readout disappoints, he maintains a 45% probability of approval for dabogratinib in urothelial carcinoma and keeps his 12‑month price target unchanged at $45, reflecting his confidence in both near‑term catalysts and longer‑term value creation.
In another report released on August 25, Canaccord Genuity also maintained a Buy rating on the stock with a $50.00 price target.